Drug intelligence / Profile preview

CC-38

Development stage: Phase 2
Lead developer: CuraCell TX
Modality: Cell Therapies
Administration: Intravenous

Overview

**CC-38** is an autologous tumor-infiltrating lymphocyte (TIL) therapy developed by CuraCell using the CytoPLY platform, which expands tumor-reactive T-cells from patient tumors to enhance cytotoxic responses against solid tumors. It improves T-cell diversity, TCR repertoire for broader neoantigen recognition, and cytokine production for prolonged anti-tumor activity compared to traditional IL-2-based methods. Currently in a Phase I/IIa trial evaluating safety, tolerability, feasibility of repeated dosing, immune responses, and preliminary efficacy in metastatic colorectal and prostate cancers.[2][5][8][11]

Beyond the preview

Go deeper on CC-38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-38.

Explore the full profile